Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N, van den Berg S, Stolwijk NN, Jacobs BAW, Post HC, Pasmooij AMG, de Visser SJ, Hollak CEM. Rosenberg N, et al. Among authors: pasmooij amg. Front Pharmacol. 2023 Feb 28;14:1142351. doi: 10.3389/fphar.2023.1142351. eCollection 2023. Front Pharmacol. 2023. PMID: 36925633 Free PMC article.
Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study.
Muurling M, Pasmooij AMG, Koychev I, Roik D, Froelich L, Schwertner E, Religa D, Abdelnour C, Boada M, Almici M, Galluzzi S, Cardoso S, de Mendonça A, Owens AP, Kuruppu S, Gjestsen MT, Lazarou I, Gkioka M, Tsolaki M, Diaz A, Gove D, Visser PJ, Aarsland D, Lucivero F, de Boer C; RADAR-AD Consortium. Muurling M, et al. Among authors: pasmooij amg. PLoS One. 2023 Jul 7;18(7):e0285807. doi: 10.1371/journal.pone.0285807. eCollection 2023. PLoS One. 2023. PMID: 37418385 Free PMC article.
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC.
Ismail RK, Schramel FMNH, van Dartel M, Pasmooij AMG, Cramer-van der Welle CM, Hilarius DL, de Boer A, Wouters MWJM, van de Garde EMW. Ismail RK, et al. Among authors: pasmooij amg. BMC Med Res Methodol. 2023 Jan 3;23(1):1. doi: 10.1186/s12874-022-01760-0. BMC Med Res Methodol. 2023. PMID: 36593440 Free PMC article.
Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC.
Ismail RK, Schramel FMNH, van Dartel M, Pasmooij AMG, der Welle CMC, Hilarius DL, de Boer A, Wouters MWJM, van de Garde EMW. Ismail RK, et al. Among authors: pasmooij amg. BMC Med Res Methodol. 2023 Jan 27;23(1):26. doi: 10.1186/s12874-023-01850-7. BMC Med Res Methodol. 2023. PMID: 36707787 Free PMC article. No abstract available.
Revising EU pharmaceutical legislation: will it foster drug repurposing?
Scholte M, Grimm SE, Pauly B, Verbeeck F, Pasmooij AMG, Bouma B, van Duijn-Wiersma J, Guney E, Kesselheim AS, Schmidt HHHW, Joore MA. Scholte M, et al. Among authors: pasmooij amg. Drug Discov Today. 2025 Jan 3:104286. doi: 10.1016/j.drudis.2024.104286. Online ahead of print. Drug Discov Today. 2025. PMID: 39756647 Free article.
90 results